Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on Kazia’s ongoing trials for its lead candidate, GDC-0084.
The interview covers:
- Kazia’s phase II study in newly diagnosed glioblastoma (GBM) patients which determined a higher maximum tolerated dose than Genentech’s phase I study in patients with recurrent disease.
- How recruiting for the phase I study in Diffuse Intrinsic Pontine Glioma (DIPG) with St Jude Children's Research Hospital is progressing well, with preliminary data anticipated in 2H2019.
- The ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.
- Kazia’s valuation compared to other US companies developing PI3K inhibitors.
Listen to the podcast here:
